Olaparib, a poly (ADP-ribose) polymerase inhibitor (PARPi), was shown to suppress MDSC migration, increasing the anti-tumor activity of epidermal growth factor receptor (EGFR) vIII-targeted CAR (806-28Z CAR) T-cells. This evidence concerns the gene EGFR and neoplasm.